Correlation Between Royalty Pharma and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both Royalty Pharma and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Royalty Pharma and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Royalty Pharma Plc and Crispr Therapeutics AG, you can compare the effects of market volatilities on Royalty Pharma and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Royalty Pharma with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Royalty Pharma and Crispr Therapeutics.

Diversification Opportunities for Royalty Pharma and Crispr Therapeutics

0.24

Correlation Coefficient

Royalty Pharma  Crispr Therapeutics

Modest diversification

The 3 months correlation between Royalty and Crispr is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Royalty Pharma Plc and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Royalty Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Royalty Pharma Plc are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Royalty Pharma i.e., Royalty Pharma and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Royalty Pharma and Crispr Therapeutics

Given the investment horizon of 90 days Royalty Pharma Plc is expected to under-perform the Crispr Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Royalty Pharma Plc is 2.57 times less risky than Crispr Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Crispr Therapeutics AG is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  4,500  in Crispr Therapeutics AG on September 25, 2024 and sell it today you would lose (409.00) from holding Crispr Therapeutics AG or give up 9.09% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	99.8%
Values	Daily Returns

Royalty Pharma Plc  vs.  Crispr Therapeutics AG

Royalty Pharma Plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Royalty Pharma Plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Crispr Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest unfluctuating performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors.

Pair Trading with Royalty Pharma and Crispr Therapeutics

The main advantage of trading using opposite Royalty Pharma and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Royalty Pharma position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind Royalty Pharma Plc and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.